 Iradimed NASDAQ:IRMD was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, iRadimed Corporation engages in developing, manufacturing, marketing, and distributing magnetic resonance imaging MRI compatible products. It offers non-magnetic intravenous IV infusion pump systems, IV tubing ... 